CNP-106

Small molecule

CCOUR Pharmaceutical Development Company, Inc.

CNP-106 is one of 48 small molecule programs targeting Myasthenia Gravis. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myasthenia GravisActive, not recruiting

Myasthenia GravisPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

102 competitors in Myasthenia Gravis

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

7 2

Ultomiris

AstraZeneca

Phase 3

5 3

Vyvgart

Argenx

Phase 3

17 4

Soliris

AstraZeneca

Phase 3

4 5

Cellcept

Roche

Phase 3

4 6

Zilbrysq

UCB

Phase 3

4 7

Fabhalta

Johnson & Johnson

Phase 3

3 8

Arava

Sanofi

Phase 3

1 9

Rhapsido

Novartis

Phase 3

1 10

ENSPRYNG

Roche

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1/2Recruiting

Myasthenia Gravis

NCT06106672

Clinical

Trials by Indication[1]

Myasthenia Gravis1 trial

Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis

Recruiting·CCOUR Pharmaceutical Development Company, Inc.·Phase 1/2·NCT06106672·54 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CNP-106. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CNP-106 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CNP-106. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — COUR Pharmaceutical Development Company, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: CCOUR Pharmaceutical Development Company, Inc.

CNP-106

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Myasthenia Gravis1 trial

References

Drug Info

Quick Facts

Related News